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Orotidine-5'-monophosphate decarboxylase (ODCase) is an enzyme that catalyzes 
the final step during the de novo synthesis of uridine-5'-monophosphate (UMP). Several 
UMP derivatives modified at the C6 position, including 6-iodouridine-5'-monophosphate, 
have exhibited potent inhibition of ODCase catalytic activity. As part of this thesis, 
various analogs of UMP were synthesized by attaching small heterocycle moieties at the 
C6 position through a C-C bond. This was achieved by exploring Stille-coupling and 
Click chemistry, to prepare four novel C6 derivatives of UMP. These derivatives are 6-
(tetrazol-4-yl)-UMP, 6-(pyrazol-4-yl)-UMP, 6-(thiophen-2-yl)-UMP and 6-(thiophen-3-
yl)-UMP, and the corresponding nucleosides. The nucleotide derivatives are under 
investigation as inhibitors of ODCase, and the nucleoside derivatives are investigated as 
potential antimalarial and anticancer agents.  Synthetic strategies, the design of inhibitors, 
and the accomplishments to isolate C6-heterocycle substituted uridine derivates in the 
context of therapeutic potential are discussed. 
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CHAPTER I 
INTRODUCTION AND BACKGROUND 
I.a. Orotidine-5'-Monophosphate Decarboxylase (ODCase) 
 Orotidine-5'-monophosphate decarboxylase (ODCase), is an essential enzyme that 
catalyses the last of six steps of the uridine-5'-monophosphate (UMP) synthesis, which 
converts orotidine-5'-monophosphate (OMP) (compound 1) to UMP (compound 2) 
(Scheme 1) (Appleby, 2000; Langely, 2008). The final product of this pyrimidine 
synthesis is UMP, which is an essential building block for other pyrimidine nucleotides 
(Meza-Avina, 2008). These nucleotides (including UMP) are vital for a number of 
cellular processes, making them indispensable for the survival of the cell (Meza-Avina, 
2008). 
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Scheme 1. Final step in the de novo synthesis of UMP (2) from OMP (1) catalyzed by 
ODCase. 
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The mechanism of reaction for ODCase is the center of a wide debate, as it is 
difficult to account for the high rate of efficiency with any of the favored reactions (Vleet, 
2008). However, the most widely accepted mechanism involves the direct removal of the 
C6 carboxylic acid group (Meza-Avina, 2008; Hu, 2008). This generates an anion at the 
C6 position, which is supposedly stabilized by Lys93 (based on yeast numbering) (Vleet, 
2008). This anion then picks up a proton to form the final product of uridine (Vleet, 2008; 
Meza-Avina, 2008). This suggested mechanism can be seen below in Scheme 2. 
 
HN
N
O
O
O
O
HO OH
2-O3P
HN
N
O
O
O
O
HO OH
2-O3P
1 2
O
O
HN
N
O
O
O
O
HO OH
2-O3P
Lys
NH
H
H
 
Scheme 2. Proposed mechanism of decarboxylation by ODCase. 
 
While the mechanism of this reaction is still being debated, crystal structures of 
the enzyme with bound UMP have been obtained (Figure 1) and show the C6 position 
buried in the active site and the residues around the area (Appleby, 2000). The enzyme is 
active as a dimer, with both monomers having an active site containing the majority of 
the residues from the monomer it is in and a few from the adjoining monomer (Langely, 
2008). Aside from its importance as a potential anti-malarial target, ODCase has also 
garnered attention through the fact that it is one of the most proficient enzymes known, 
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increasing the rate of decarboxylation by a factor of 1017 without the use of any cofactors 
(Langely, 2008; Vleet, 2008).  
Although the catalytic mechanism of decarboxylation by ODCase is not 
completely understood, the crystal structures of known inhibitors with ODCase have 
shown the residues around the C6 and C5 positions, opening doors for the design of 
inhibitors of this enzyme (Appleby, 2000; Bello, 2008). Some C6 derivatives of UMP 
already exist that have been shown to inhibit malarial ODCase, including 6-iodo-UMP 
(Bello, 2007; Poduch, 2006). Another basis for design of inhibitors is on the substrate, 
orotidine-5'-monophosphate (OMP). From these two starting points, several ideas for 
inhibitors were designed based on substitutions at the C6 position of uridine-5'-
monophosphate (UMP). 
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Figure 1. Crystal structure of Pf ODCase monomer with bound UMP (Bello, 2008).  
 
I.b. Therapeutic Application  
Malaria is a parasitic disease caused by the Plasmodia genus, which consists of P. 
falciparum, P. vivax, P. ovale and P malariae (Meza-Avina, 2008; Vera, 2009). The life 
cycle of this parasite consists of three stages. Initially, the infected mosquito injects the 
sporozoites into the lymph which puts them in circulation. Once these sporozoites reach 
the liver, they develop into merozoites which then exit from the liver and invade red 
blood cells (Good, 2009). Here, they either continue to develop more merozoites and 
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eventually rupture the cell, or develop into gametocytes which are then passed on to a 
new mosquito to spread the parasite. The life cycle of the malaria parasite can be seen in 
Figure 2 (Good, 2009).  
 
 
Figure 2. Schematic of the life cycle of the malaria parasite (Good, 2009).  
 
 
Malaria poses a great threat to developing countries, predominantly in Africa. It is 
estimated that there were 247 million cases of malaria in 2006, resulting in approximately 
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881,000 deaths (World Health Organization, 2008). Of these, they report that 91% of 
these deaths were in Africa, while 4% occurred in both the South-East Asia and Eastern 
Mediterranean regions. Even though it is most prevalent in African countries it is still 
present around the world, with the WMR 2008 reporting that there were 109 countries 
and territories with malaria present. Malaria’s spread specifically throughout African 
countries has led the WHO to label the disease as an endemic.  
Malaria is starting to spread outside of its once shrinking areas, predominantly in 
developing countries, mainly due to newly emerging drug-resistant strains (Verra, 2009; 
Choi, 2008). This increase has caused a widespread interest in the finding of vaccines and 
new drugs, as well as combination therapy with existing drugs (Verra, 2009; Good, 2009). 
Special emphasis is placed on making these new products affordable and easily available, 
since most of the people of these countries are unable to access preventative measures, 
such as treated mosquito nets, and the current drugs and combination therapies necessary 
once they are infected (Verra, 2009). Of the Plasmodia genus, P. falciparum(Pf) is the 
most widespread in humans, as well as having the most severe symptoms and highest 
instance of resulting deaths, followed by P. vivax (Bello, 2008).  
Plasmodial ODCase presents itself as a good antimalarial target for multiple 
reasons.  In Plasmodia, the de novo pathway is the only source of pyrimidine nucleotides, 
as these parasites have neither pyrimidine transporters or a salvage pathway.  Whereas in 
human, both a salvage pathway and a de novo pathway are operational, providing an 
opportunity to design ODCase inhibitors that would be nontoxic (Bello, 2008). So if 
ODCase is knocked out by inhibition, even in the human, the human can still generate the 
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necessary nucleic bases while the parasite will be unable to reproduce and function 
normally, leading to it’s death. While the focus of therapeutic application is on 
antimalarials, the target of inhibition of these compounds also leads to potential 
anticancer effects (Meza-Avina, 2008). The final product of the pyrimidine pathway, 
UMP, is essential to both DNA and RNA (UMP is an essential building block of the 
RNA and a precursor to both thymidine and cytidine nucleotides). Thus the inhibitors of 
ODCase could exhibit potential inhibition of cell proliferation, leading to anticancer 
effects. With this in mind, all synthesized compounds are also tested against cancer cell 
lines. 
 
I.c. Methods of Malarial Inhibition 
One of the main targets of the malaria causing Plasmodia species is the de novo 
synthesis of pyrimidines (Choi, 2008). This 6 step synthesis has many potential targets. 
Of these, two enzymes are the focus of most antimalarial research for this pathway. 
Those are dihydroorotate dehydrogenase (DHODH) which catalyzes the fourth step of 
the synthesis, and orotidine 5’-monophosphate decarboxylase (ODCase), which catalyzes 
the sixth and final step of the synthesis of uridine (Heikkila, 2007; Hurt, 2006).  ODCase 
is the target chosen for the present study. 
Also being researched for potential antimalarial treatments are enzymes of the 
purine salvage pathway and of the folate synthesis pathway (antifolates) (Kouni, 2003; 
Rodenko, 2006; Nzila, 2006). The purine synthesis pathway is under some scrutiny for 
similar reasons as the pyrimidine pathway, except in the purines case the parasites have 
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only a salvage pathway (Kouni, 2003; Rodenko, 2006). Some of the major enzymes in 
this pathway are potential targets for combination therapy inhibition, although this is still 
a developing field (Kouni, 2003). Finally, antifolates are used to target enzymes, mainly 
dihydrofolate reductase (DHFR), of the folate synthesis pathway (Yuthavong, 2005; 
Nzila, 2006). Multiple groups are studying new antifolates, as resistance is growing to the 
ones presently on the market, although no new antifolates as antimalarials have made it to 
the market besides the originals in the 1940s ( Hunt, 2005; Vilaivan, 2003; Muregi, 2009).  
 
I.d. Rationale 
Based on the crystal structures of ODCase, it could be seen that there is a 
hydrophobic pocket situated adjacent to the C5 position when 6-iodo-UMP was bound 
(Bello, 2008). This pocket suggested the possibility of placing hydrophobic groups at the 
C5 or C6 position of UMP to promote strong binding of the proposed inhibitor to the 
enzyme. In this case, the focus was placed on derivatives at the C6 position. This 
reasoning led to the decision to try to place thiophene and furan heterocycles at this 
desired position, specifically through a carbon-carbon bond. Another hydrophobic 
possibility looked at for a C6 derivative of UMP was a tributyltin group. 
When basing the design of the derivatives on the substrate, two strategies were 
adopted based on the discoveries thus far in Kotra laboratory: First was to identify 
methods to synthesize a nitro group at the C6 position. It was conceived by Profs. Kotra 
and Pai that the similarities between the carboxylic acid group (at the C6 position of 
OMP) and a nitro group are isoelectronic, with both the charge and the size of the two 
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groups being similar. However, the nitro group is perceived to be resistant to removal by 
ODCase from the C6 position and such compounds will aid in the elucidation of 
mechanism of decarboxylation of OMP, as well as potentially could be an inhibitor of 
this enzyme. 
The other strategy is to replace the carboxylic acid group with a tetrazole through 
a C-C bond. Tetrazole rings have been used multiple times in past medicinal chemistry to 
replace carboxylic acids, as they are bioisosteres of each other, meaning they have similar 
physicochemical properties, and so will act similarly under biological conditions (Herr, 
2002). Because of the free N-H bond present on tetrazole, they are acidic molecules and 
have a similar pKa to carboxylic acid (Herr, 2002). Other similarities include the planar 
structure, and the fact that tetrazoles are ionized at physiological pH (Herr, 2002). Very 
importantly, unlike carboxylic acids, tetrazoles have shown resistance to many biological 
metabolic degradation pathways (Herr, 2002). 
 
I.e. Retrosynthetic Analysis 
After deciding on the compounds to be synthesized, retrosynthetic analysis was 
used to design a synthesis pathway for the desired compounds. Although the desired 
compound is based on UMP (1), the monophosphate group is very reactive and easily lost, 
so uridine (3) was used as a starting material. The reactivity of the free hydroxyl groups 
on the sugar ring required their protection before further reactions were carried out. This 
protection was performed by placing a tert-butyldimethyl silyl (TBDMS) moiety at the 5' 
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position and an isopropylidene group at the 2’ and 3’ positions using known methods 
(Bello, 2007).  
The resulting fully protected uridine was then subjected to different procedures, 
based on the desired product, to be modified at the C6 position. These coupling 
procedures include Stille coupling, Click chemistry and conventional nucleophiles to 
generate the C-C coupled products.  The focus for these modifications was primarily on 
heterocycles connected to C6 through C-C bonds. Finally, the protecting groups were 
removed and the monophosphate was added to the 5' hydroxyl moiety (Bello, 2007). This 
general synthesis can be seen in Scheme 3.  
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Scheme 3. General scheme for synthesis of C6 derivatives of UMP. Reaction conditions: 
a) acetone, H2SO4 b) CH2Cl2, imidazole, TBDMSCl, 0 °C→RT c) Specific to derivative 
d) 50% trifluoroacetic acid in H2O, 0 °C→RT e) H2O, POCl3, acetonitrile, pyridine, 0 °C, 
NH4OH. 
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This method of design resulted in the successful synthesis of eight novel compounds that 
can be seen in Figure 3. 
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Figure 3. Final successfully synthesized novel compounds. 6-(thiophen-3-yl) uridine (6), 
6-(thiophen-2-yl) uridine (8), 6-(pyrazol-4-yl) uridine (10) and 6-(tetrazol-4-yl) uridine 
(12), along with the corresponding nucleotides, 6-(thiophen-3-yl) uridine-5'-
monophosphate (7), 6-(thiophen-2-yl) uridine-5'-monophosphate (9), 6-(pyrazol-4-yl) 
uridine-5'-monophosphate (11) (impure) and 6-(tetrazol-4-yl) uridine-5'-monophosphate 
(13) (impure).
 
CHAPTER II 
MATERIALS AND METHODS 
II.a. General Materials 
Uridine and all reagents and solvents were obtained from commercially available 
sources. Argon was used for all reactions that were carried out under anhydrous 
conditions. Thin layer chromatography plates (TLC) silica gel 60 F254 were used to 
monitor reactions. Charring of TLCs was done using KMnO4. For column 
chromatography purification on manual and Biotage™ separation system columns, 63-
200 µm, 60Å silica gel was used. For purification using reverse phase column 
chromatography, C18 silica gel was used. Biotage™ column sizes used were 10 g, 25 g 
and 60 g for regular phase, and 12 g and 60 g for reverse phase C18. For purification and 
analytical analysis using HPLC, Atlantis T3 preparatory and analytical C18 columns 
were used on a Varian ProStar. All 1H, 13C and 31P NMRs were obtained using a 500 
MHz JEOL NMR instrument. 31P NMRs were referenced to 0 ppm using H3PO4. UV and 
epsilon values were obtained using a Varian.  
 
II.b. Synthesis 
2',3'-O-isopropylidene uridine (4).  A stirred suspension of anhydrous acetone (100 mL) 
and uridine 1 (2.0 g, 8.2 mmol) was brought to 0 °C and sulfuric acid (1.0 mL) was added 
dropwise. After 5 minutes, ice was removed and mixture was allowed to stir at room 
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temperature for 1.5 hours. Et3N was then added to neutralize and reaction mixture was 
filtered and concentrated. The crude mixture was then purified using silica gel column 
chromatography (4-8% MeOH: CH3Cl) to obtain the product as a white solid (1.43 g, 
61%). 1H NMR (CDCL3) δ 1.31 (s, 3H, CH3), 1.53 (s, 3H, CH3), 3.74 (dd, 1H, H-5'’), 
3.83 (dd, 1H, H-5'), 4.24 (m, 1H, H-4'), 4.88 (dd, 1H, H-3'), 4.92 (dd, 1H, H-2'), 5.62 (d, 
1H, H-1'), 5.70 (d, 1H, H-5), 7.46 (d, 1H, H-6).  
 
5'-O-tert-Butyldimethylsilyl-2',3'-O-isopropylidene uridine (5).  A solution was made of 
2',3'-O-isopropylidene uridine (4) (1.2 g, 4.2 mmol) and anhydrous CH2Cl2 (18 mL) at 
0 °C. Imidazole (0.77 g, 11.3 mmol) and tert-butyldimethylsilyl chloride (0.83 g, 5.4 
mmol) were added and mixture was allowed to return to room temperature and stirred for 
2 hours. Once reaction was complete, the crude mixture was evaporated and the solid 
dissolved in ethyl acetate (30 mL), washed with water (15 mL) and brine (15 mL) and 
dried with Na2SO4 and concentrated. The crude solid was purified using silica gel column 
chromatography (0-5% MeOH:CHCL3). Pure product was concentrated to 1.21 g (72%) 
as a white solid. 1H NMR (CDCL3) δ 0.07 (s, 6H, CH3), 0.88 (s, 9H, CH3), 1.34 (s, 3H, 
CH3), 1.57 (s, 3H, CH3), 3.77 (dd, 1H, H-5'’), 3.89 (dd, 1H, H-5'), 4.31 (m, 1H, H-4'), 
4.66 (dd, 1H, H-3'), 4.73 (dd, 1H, H-2'), 5.65 (d, 1H, H-5), 5.96 (d, 1H, H-1'), 7.68 (d, 1H, 
H-6), 8.49 (brs, 1H, -NH). 
 
5'-O-tert-Butyldimethylsilyl-6-iodo-2',3'-O-isopropylidene uridine (22). A solution was 
made of 5'-O-tert-butyldimethylsilyl-2',3'-O-isopropylidene uridine 5 (2.0 g, 5.0 mmol) 
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in anhydrous THF (10 mL) at -78 °C. LDA (6.52 mL, 13.0 mmol, 2 M solution in THF) 
was added dropwise and mixture was allowed to stir for 1 hour at -78 °C. After 1 hour, 
iodine (1.53 g, 6.0 mmol) in anhydrous THF (5 mL) was added and mixture was stirred 
for 2.5 hours at -78 °C. Reaction was then quenched with 4.2 mL water and dissolved in 
ethyl acetate (40 mL), washed with brine (25 mL) and dried with Na2SO4. Crude mixture 
was then concentrated and purified using silica gel column chromatography (0-30% ethyl 
acetate:hexanes) and 1.0 g (38%) pure compound was obtained as a dark yellow solid. 
UV (CHCl3): λmax=268 nm. 1H NMR (CDCL3) δ 0.08 (s, 6H, CH3), 0.90 (s, 9H, CH3), 
1.30 (s, 3H, CH3), 1.51 (s, 3H, CH3), 3.75 (m, 2H, H-5', H-5'’), 4.13 (m, 1H, H-4'), 4.77 
(dd, 1H, H-3'), 5.14 (dd, 1H, H-2'), 6.04 (d, 1H, H-1'), 6.40 (s, 1H, H-5), 9.43 (brs, 1H, -
NH). 
 
5'-O-tert-Butyldimethylsilyl-2',3'-O-isopropylidene-6-tributyltin uridine (14). Used 
same method as above, replacing iodine with tributyltin chloride (10.0 mmol, 2 
equivalents). Crude mixture was purified using silica gel column chromatography (0-20% 
ethyl acetate:hexanes), giving 2.66 g (77%)  of pure product as a yellow oil. UV (CHCl3): 
λmax=269 nm; 1H NMR (CDCL3) δ 0.01 (s, 6H, CH3), 0.67-1.65 (m, 42H), 3.78 (m, 2H, 
H-5', H-5'’), 4.08 (m, 1H, H-4'), 4.76 (dd, 1H, H-3'), 5.17 (dd, 1H, H-2'), 5.26 (d, 1H, H-
1'), 5.67 (s, 1H, H-5), 8.05 (brs, 1H, -NH). 
 
5'-O-tert-Butyldimethylsilyl-6-(furan-2-yl)-2',3'-O-isopropylidene uridine. 
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 Used same method as above, replacing iodine with 3-bromofuran (5.5 mmol, 1.1 
equivalents). Additional quenching methods tried on separate reaction attempts included 
saturated NH4Cl solution, and a 1:1 saturated NH4Cl:ethyl acetate solution, both followed 
by work-up in above procedure. Clean product not obtained. 
 
5'-O-tert-Butyldimethylsilyl -2',3'-O-isopropylidene-6-(thiophene-3-yl) uridine (17).  A 
solution of 5'-O-tert-butyldimethylsilyl-2',3'-O-isopropylidene-6-tributyltin uridine (14) 
(0.20 g, 0.29 mmol) in DMF (5 mL) was added to a flask with CuI (0.0114 g, 0.060 
mmol), Pd(TPP)4 (0.035 g, 0.030 mmol) and 3-iodothiophene (0.04 mL, 0.39 mmol). The 
reaction mixture was stirred at 80 °C for 1.5 hours. The reaction mixture was allowed to 
return to room temperature, and was treated with saturated NH4Cl (15 mL), then 
extracted twice with ethyl acetate (20 mL). Organic layers were combined and washed 
with saturated KF·H2O (20 mL), twice with water (20 mL) and brine (20 mL). Reaction 
mixture was then dried with MgSO4 and concentrated. Crude product was then purified 
using silica gel column chromatography (0-30% ethyl acetate:hexanes). Pure product 
obtained as white solid with 91% yield (0.13 g). UV (CHCl3) λmax=278 nm; 1H NMR 
(Acetone-d6) δ 0.06 (s, 6H, CH3), 0.90 (s, 9H, CH3), 1.27 (s, 3H, CH3), 1.35 (s, 3H, CH3), 
3.85 (m, 2H, H-5', H-5'’), 4.04 (m, 1H, H-4'), 4.81 (dd, 1H, H-3'), 5.28 (dd, 1H, H-2'), 
5.57 (d, 1H, H-1'), 5.63 (d, 1H, H-5), 7.37 (d, 1H, H-4'’), 7.73 (d, 1H, H-2'’), 7.90 (d, 1H, 
H-5'’’). 
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5'-O-tert-Butyldimethylsilyl-2',3'-O-isopropylidene-6-(thiophene-2-yl) uridine (16). 
Used same method as above, replacing 3-iodothiophene with 2-iodothiophene (0.39 
mmol, 1.3 equivalents).  Crude product was then purified using silica gel column 
chromatography (0-30% ethyl acetate:hexanes). Pure product obtained as white solid 
with 90% yield (0.11 g). UV (CHCl3): λmax=275 nm; 1H NMR (CDCL3) δ 0.06 (s, 6H, 
CH3), 0.90 (s, 9H, CH3), 1.27 (s, 3H, CH3), 1.36 (s, 3H, CH3), 3.85 (m, 2H, H-5', H-5'’), 
4.06 (m, 1H, H-4'), 4.81 (dd, 1H, H-3'), 5.28 (dd, 1H, H-2'), 5.69 (d, 1H, H-1'), 5.74 (s, 
1H, H-5), 7.26 (dd, 1H, H-4'’), 7.51 (dd, 1H, H-3'’), 7.81 (dd, 1H, H-5'’’). 
 
5'-O-tert-Butyldimethylsilyl-6-(furan-2-yl)-2',3'-O-isopropylidene uridine 
Used same method as above, replacing 3-iodothiophene with 2-bromofuran (0.39 mmol, 
1.3 equivalents). Clean product was not obtained. 
 
5'-O-tert-Butyldimethylsilyl-2',3'-O-isopropylidene-6-(imidazol-4-yl) uridine 
Used same method as above, replacing 3-iodothiophene with 4-iodoimidazole (0.39 
mmol, 1.3 equivalents). Clean product was not obtained. 
  
5'-O-tert-Butyldimethylsilyl -2',3'-O-isopropylidene-6-(pyrazol-4-yl) uridine (15).  
Used same method as above, replacing 3-iodothiophene with 4-iodopyrazole (0.39 mmol, 
1.3 equivalents). Crude product was purified using silica gel column chromatography (0-
4% MeOH:CHCl3). Pure product was obtained as white solid with 50% yield (0.068 g). 
UV (CHCl3): λmax=279 nm; 1H NMR (CDCL3) δ 0.04 (s, 6H, CH3), 0.89 (s, 9H, CH3), 
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1.29 (s, 3H, CH3), 1.44 (s, 3H, CH3), 3.83 (m, 2H, H-5', H-5'’), 4.13 (m, 1H, H-4'), 4.83 
(dd, 1H, H-3'), 5.21 (dd, 1H, H-2'), 5.67 (d, 1H, H-1'), 5.76 (s, 1H, H-5), 7.93 (s, 2H, H-
3'’, H-5'’’), 9.14 (brs, 1H, -NH); MS (ESI) calculated (M+Na+) 487.2, observed 487.2.  
 
5-Bromo-5'-O-tert-butyldimethylsilyl-2',3'-O-isopropylidene uridine (18). To a stirred 
suspension of 5'-O-tert-butyldimethylsilyl-2',3'-O-isopropylidene uridine (5) (2.0 g, 5.0 
mmol) in 1,2-dimethoxy ethane (40 mL) was added a solution of NaN3 (1.305 g, 20.1 
mmol) in water (6 mL). N-Bromosuccinimide (0.982 g, 5.5 mmol) was added and 
reaction was stirred at room temperature for 24 hours. Crude mixture was concentrated 
and dissolved in ethyl acetate (20 mL), extracted with water (20 mL) and dried with 
Na2SO4. Reaction mixture was clean with quantitative yield (2.44 g) and was taken 
directly to next step. UV (CHCl3): λmax=278 nm; 1H NMR (CDCL3) δ 0.06 (s, 6H, CH3), 
0.85 (s, 9H, CH3), 1.30 (s, 3H, CH3), 1.53 (s, 3H, CH3), 3.74 (dd, 1H, H-5'’), 3.87 (dd, 
1H, H-5'), 4.34 (m, 1H, H-4'), 4.65 (dd, 1H, H-3'), 4.67 (dd, 1H, H-2'), 5.87 (d, 1H, H-1'), 
7.86 (s, 1H, H-6), 9.88 (brs, 1H, -NH). 
 
6-Cyano-5'-O-tert-butyldimethylsilyl-2',3'-O-isopropylidene uridine (19).  Anhydrous 
DMF (20 mL) was added to 5-bromo-5'-O-tert-butyldimethylsilyl-2',3'-O-isopropylidene 
uridine (18) (1.78 g, 3.7 mmol) and NaCN (0.2923 g, 5.96 mmol). The reaction mixture 
was allowed to stir at room temperature 12 hours, and then was brought to pH 6 with 
10% HCl and extracted with ethyl acetate (20 mL) and water (15 mL), washed with brine 
(20 mL) and dried with Na2SO4. The product has the same chromatographic shift on the 
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TLC as that of starting material, and the product was identified using UV spectroscopy 
prior to purification. The product was purified using silica gel column chromatography 
(0-40% ethyl acetate:hexanes), to give 1.01 g (64%) of product as a white solid. UV 
(CHCl3): λmax=283 nm; 1H NMR (CDCL3) δ 0.04 (s, 6H, CH3), 0.88 (s, 9H, CH3), 1.33 (s, 
3H, CH3), 1.51 (s, 3H, CH3), 3.81 (m, 2H, H-5', H-5'’), 4.13 (m, 1H, H-4'), 4.75 (dd, 1H, 
H-3'), 5.11 (dd, 1H, H-2'), 6.02 (d, 1H, H-1'), 6.27 (s, 1H, H-5), 8.27 (brs, 1H, -NH). 
 
5'-O-tert-Butyldimethylsilyl-2',3'-O-isopropylidene-6-(tetrazol-4-yl) uridine (20) and 
2',3'-O-isopropylidene-6-(tetrazol-4-yl) uridine (side product;21).  Anhydrous DMF (10 
mL) was added to 6-cyano-5'-O-tert-butyldimethylsilyl-2',3'-O-isopropylidene uridine 19 
(0.837 g, 2.0 mmol), NaN3 (0.1413 g, 2.2 mmol) and NH4Cl (0.116 g, 2.2 mmol) and 
mixture was stirred at 90 °C for 2 hours. Reaction mixture was then allowed to return to 
room temperature and water (30 mL) was added. Since no precipitate was seen, the 
mixture was then extracted with ethyl acetate, with most of the product going into the 
aqueous layer. Both layers were evaporated separately and were purified using silica gel 
column chromatography on a Biotage system (0-20% MeOH:CHCl3). The product was 
eluted at 15% MeOH:CHCl3. The total yield of the crude product including the side 
product was 0.475 g (58%) obtained as a white solid. UV (MeOH): λmax= 274 nm; 1H 
NMR (DMSO-d6) δ 0.01 (s, 6H, CH3), 0.84 (s, 9H, CH3), 1.29 (s, 3H, CH3), 1.44 (s, 3H, 
CH3), 3.73 (m, 2H, H-5', H-5'’), 3.89 (m, 1H, H-4'), 4.71 (dd, 1H, H-3'), 5.23 (dd, 1H, H-
2'), 5.88 (d, 1H, H-1'), 6.76 (s, 1H, H-5), 11.48 (brs, 1H, -NH). 
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6-(Thiophene-2-yl) uridine (8).  5'-O-tert-Butyldimethylsilyl-6-(thiophene-2-yl)-2',3'-O-
isopropylidene uridine (0.3 g, 0.5 mmol) was placed in a flask at 0 °C and 3 mL of a 50% 
aqueous solution of trifluoroacetic acid was added. After 10 minutes, reaction was 
allowed to return to room temperature and stirred for an additional 2 hours. The reaction 
mixture was then concentrated. Crude compound was washed with water, the solvent was 
evaporated twice more to remove excess TFA. Crude compound was purified using silica 
gel column chromatography (0-8% MeOH:CHCl3) to obtain a pure product as a very pale 
yellow solid (0.113 g, 55%). UV (MeOH): λmax=275 nm (ε=6368), 1H NMR (MeOH-d4) 
δ 3.55 (m, 1H, H-5'’), 3.67 (m, 2H, H-4', H-5'), 4.17 (dd, 1H, H-3'), 4.62 (dd, 1H, H-2'), 
5.41 (d, 1H, H-1'), 5.61 (s, 1H, H-5), 7.07 (dd, 1H, H-4'’), 7.42 (dd, 1H, H-2'’), 7.57 (dd, 
1H, H-5'’’)  MS (ESI): Calculated (M+Na+) 349.33, observed 349.05. 97% pure (HPLC). 
 
6-(Thiophene-3-yl) uridine (6). Used same method as above, replacing the starting 
material with 5'-O-(tert-butyldimethylsilyl)-2',3'-O-isopropylidene-6-(thiophene-3-yl) 
uridine (0.350 g, 0.58 mmol). Crude compound was purified using silica gel column 
chromatography (0-8% MeOH:CHCl3) to obtain the pure product (0.167 g, % yield) as a 
white solid. UV (MeOH): λmax=276 nm (ε=9115), 1H NMR (MeOH-d4) δ 3.54 (m, 1H, 
H-5'’), 3.65 (m, 2H, H-4', H-5'), 4.14 (dd, 1H, H-3'), 4.59 (dd, 1H, H-2'), 5.24 (d, 1H, H-
1'), 5.54 (s, 1H, H-5), 7.23 (dd, 1H, H-4'’), 7.47 (dd, 1H, H-2'’), 7.71 (dd, 1H, H-5'’’). MS 
(ESI): Calculated (M+Na+) 349.33, observed 349.05. 99% pure (HPLC). 
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6-(Pyrazol-4-yl) uridine (10).  Used same method as above, replacing the starting 
material with 5'-O-(tert-butyldimethylsilyl)-2',3'-O-isopropylidene-6-(pyrazol-4-yl) 
uridine (0.160 g, 0.34 mmol). To make crude product soluble in water, 1 M NH4OH  was 
added dropwise until full solubility was achieved. The resulting mixture was then loaded 
on a C18 reverse silica gel column. The product came with the solvent front in 100% 
water. 0.064 g (60%) pure product obtained as white solid. UV (H2O): λmax= 278 nm 
(ε=9607), 1H NMR (D2O with NH4OH) δ 3.63 (m, 1H, H-5'’), 3.74 (m, 2H, H-4', H-5'), 
4.18 (dd, 1H, H-3'), 4.77 (peak overlaps D2O, 1H, H-2'), 5.48 (d, 1H, H-1'), 5.64 (s, 1H, 
H-5), 7.83 (s, 2H, H-3'’, H-5'’’). 96% pure (HPLC). 
 
6-(Tetrazol-4-yl) uridine (12).  Used same method as above, replacing the starting 
material with 5'-O-(tert-butyldimethylsilyl)-2',3'-O-isopropylidene-6-(tetrazol-4-yl) 
uridine (0.200 g, 0.43 mmol). Crude compound purified using C18 reverse phase silica 
gel, 100% water. Pure compound obtained in quantitative yield (0.134 g, quantitative 
yield) as a white solid. UV (H2O): λmax = 274 nm (ε = 9460), 1H NMR (DMSO-d6) δ 3.31 
(dd, 1H, H-5'’), 3.46 (dd, 1H, H-5'), 3.56 (m, 1H, H-4'), 3.90 (dd, 1H, H-3'), 4.51 (dd, 1H, 
H-2'), 5.38 (d, 1H, H-1'), 6.03 (s, 1H, H-5), 11.76 (brs, 1H, -NH). 97% pure (HPLC). 
 
6-(Thiophene-2-yl) uridine-5'-monophosphate (9).  Anhydrous CH3CN (2.5 mL) was 
added to flask with H2O (7.57 µL, 0.44 mmol) and pyridine (0.058 mL, 0.75 mmol). 
Flask was brought to 0 °C and POCl3 (0.060 mL, 0.69 mmol) was added. The reaction 
mixture was allowed to stir for 10 minutes at 0 °C and then added to 6-(thiophene-2-yl) 
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uridine (0.051 g, 0.16 mmol) under anhydrous conditions. Mixture was allowed to stir at 
0 °C for two hours, and then at room temperature for an additional two hours. Cold water 
(15 mL) was then added and reaction mixture was allowed to stir at room temperature for 
another hour. Reaction mixture was then evaporated and crude mixture was run on a 
dowex ion exchange column (0-6% formic acid:water) to purify. Crude mixture was then 
concentrated and neutralized at 0 °C with 40% NH4OH solution. Crude mixture was 
again concentrated and purified using C18 reverse phase silica gel column, coming in 
100% water. Pure product was obtained as white solid (0.026 g, 38%). UV (H2O): λmax= 
275 nm (ε=2428), 1H NMR (D2O) δ 3.53 (m, 1H, H-5'’), 3.59 (m, 1H, H-5'), 3.66 (m, 1H, 
H-4'), 4.11 (dd, 1H, H-3'), 4.82 (peak overlaps D2O, 1H, H-2'), 5.35 (d, 1H, H-1'), 5.73 (s, 
1H, H-5), 7.00 (dd, 1H, H-4'’), 7.25 (dd, 1H, H-3'’), 7.50 (dd, 1H, H-5'’’). 31% pure 
(HPLC). 
 
6-(thiophene-3-yl) uridine-5'-monophosphate (7).  Used same method as above, 
replacing starting material with 6-(thiophene-3-yl) uridine (0.051 g, 0.16 mmol). Pure 
compound obtained as white solid 0.001 g (1.5%). UV (H2O): λmax= 276 nm (ε=4290), 
1H NMR (D2O) δ 3.69 (m, 1H, H-5'’), 3.78 (m, 1H, H-5'), 3.90 (m, 1H, H-4'), 4.18 (dd, 
1H. H-3'), 5.24 (d, 1H, H-1'), 5.68 (s, 1H, H-5), 7.11 (dd, 1H, H-4'’), 7.43 (dd, 1H, H-2'’), 
7.62 (dd, 1H, H-5'’’) MS (ESI): Calculated (M-2NH3+Na+) 429.01, observed 429.01. 
Amount insufficient for purity testing. 
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6-(Pyrazol-4-yl) uridine-5'-monophosphate (11, impure).  Used same method as above, 
replacing starting material with 6-(pyrazol-4-yl) uridine (0.050 g, 0.16 mmol). 
Concentrated and neutralized crude reaction mixture at 0 °C with 40% NH4OH solution 
and purified using C18 reverse phase silica gel column, product coming with 1% acetic 
acid in water. Impure compound obtained as white solid (0.038 g of impure compound). 
UV (H2O): λmax = 280 nm, (ε=791), 1H NMR (D2O; obtained for impure compound) δ 
3.89 (m, 2H, H-5'’, H-5'), 4.02 (m, 1H, H-4'), 4.36 (dd, 1H, H-3'), 5.59 (d, 1H, H-1'), 5.84 
(s, 1H, H-5), 7.98 (s, 2H, H-3'’, H-5'’’).  
 
6-(Tetrazol-4-yl) uridine-5'-monophosphate (13, impure).  Used same method as above, 
replacing starting material with 6-(tetrazol-4-yl) uridine (0.100 g, 0.32 mmol). Mixture of 
product and starting material obtained (0.060 g), unable to be purified using C18 reverse 
phase silica gel column. Achieved separation on analytical reverse phase HPLC (0-20% 
CH3CN:1% HCl aqueous solution). UV (H2O): λmax = 274 nm, 1H NMR (D2O; obtained 
for impure compound) δ ppm 3.88 (m, 2H, H-5'’, H-5'), 4.01 (m, 1H, H-4'), 4.31 (dd, 1H, 
H-3'), 5.43 (d, 1H, H-1'), 6.02 (s, 1H, H-5). 
 
 
II.c. Biological Testing  
Anticancer Activity  
Anticancer activity evaluations were performed by Dr. Danijela Konforte (Prof. 
Christopher Paige’s laboratory) at Ontario Cancer Institute, Princess Margaret Hospital, 
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Toronto, Ontario, Canada.  All successfully synthesized nucleosides were screened for 
their potential growth inhibition activity on OCI-AML1 cell line isolated from acute 
myeloid leukemia patients, and was a gift from Dr. M. Minden’s lab at the Ontario 
Cancer Institute in Ontario, Canada. OCI-AML1 cells were grown in Iscove’s MDM 
supplemented with 5% fetal calf serum (FCS). The in vitro cell proliferation assay was 
carried out by WST.1 assay (water soluble tetrazolium salt: 4-[3-(4-iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate), which is a colorimetric assay for 
the nonradioactive quantification of cell proliferation, cell viability and cytotoxicity. It 
relies on the cleavage of WST.1 to formazan by cellular enzymes. The amount of 
formazan dye formed correlates to the number of metabolically active cells in the culture 
and is readily read in an ELISA microplate reader using an absorbance wavelength of 440 
nm. These OD values were plotted against concentrations of different compounds and 
inhibition constant 50 (IC50) was determined for each compound.  
Antimalarial Activity  
Antimalarial activities were evaluated in the laboratories of Dr. Ian Crandall 
(Department of Laboratory Medicine and Pathobiology, University of Toronto) and Dr. 
Kevin Kain (Department of Medicine, University of Toronto). Assays comparing the 
antiplasmodial activities of the inhibitors were performed using the SYBR-Green method 
against P. falciparum (3D7) strain. A known concentration of the inhibitor and RPMI-A  
medium was treated with parasite culture (2% hematocrit, 2% parasitemia) and incubated 
for 48 hours at 37 °C. Relative fluorescence was then determined using a Fluostar Optima 
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plate reader. After this, IC50 values of the inhibitor could be determined using nonlinear 
regression analysis of the data using the computer program SigmaPlot.  
ODCase Inhibition Activity 
Inhibition of ODCase activities was conducted by Ms. Ewa Poduch at Toronto 
General Research Institute, University Health Network, Toronto, Ontario, Canada. The 
ODCase inhibitory properties of the synthesized compounds were evaluated using 
isothermal titration calorimetry (ITC). The reaction buffer typically consisted of 50 mM 
Tris, 20 mM DTT and 40 mM NaCl, adjusted to pH 7.5. The inhibition assay was 
initiated by coinjection of the OMP as substrate and the inhibitor into the ITC sample 
chamber and change in heat was measured as the reaction progressed until the heat 
returned to baseline, indicating the end of the reaction. The final substrate concentration 
was typically 40 μM in the reaction cell. The inhibition constant for the inhibitors was 
calculated either by direct fitting of the linear portions of the thermogram into the fitting 
function of Origin software or by Dixon plot method. 
 
 
CHAPTER III 
RESULTS AND DISCUSSION 
III.a. Stille Coupling 
 For three of the four final compounds successfully synthesized, 6-
(pyrazol-4-yl) UMP (11), 6-(thiophen-2-yl) UMP (9) and 6-(thiophen-3-yl) UMP (7), 
Stille Coupling was used to establish the C-C bond between C6 of uridine and the 
heterocycle. Stille-coupling employs the use of a stannane on an aryl halide to produce a 
C−C bond (Scheme 4). This method was ideal, as the intermediate, 5'-O-(tert-
butyldimethylsilyl)-6-tributyltin-2',3'-O-isopropylidene uridine, had been previously 
synthesized successfully (Scheme 5) (Palmisano, 1993). Another incentive for the use of 
this method was the versatility, as it was projected to work with any heterocycle 
containing a halide group. Of the five heterocycles used, three produced the desired 
product, with two of those three having desirable yields of ≥90%.  
To produce the intermediate, 6-tributyltin fully protected uridine (14) was 
synthesized. This was done according to a known procedure reported by Giovanni 
Palmisano and his group (Palmisano, 1993). The synthesis was successful with a 71% 
yield. The synthesis for this intermediate is presented in Scheme 5. 
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Scheme 4. Reaction mechanism for Stille coupling. L= triphenylphosphine. 
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Scheme 5. General synthesis for formation of 6-tributyltin intermediate from fully 
protected uridine. (a) LDA, THF, -78 °C, n-Bu3SnCl. 
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The three methods using heterocycles that achieved success were using 2-
iodothiophene, 3-iodothiophene and 4-iodopyrazole to give the 2-thiophenyl protected 
uridine (16), 3-thiophenyl protected uridine (17), and 4-pyrazolyl protected uridine (15), 
respectively, seen in Scheme 6. For 2-iodothiophene and 3-iodothiophene (Scheme 4b 
and 4c, respectively), the method was successful with up to 90% yields. The byproducts 
produced were very different in polarity, allowing easy separation.  
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Scheme 6. Schemes for formation of compounds synthesized using Stille coupling. (a) 
DMF, Pd(TPP)4, 4-Iodopyrazole, CuI, 80 °C (b) DMF, Pd(TPP)4, 2-Iodothiophene, CuI, 
80 °C (c) DMF, Pd(TPP)4, 3-Iodothiophene, CuI, 80 °C. 
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The method of direct nucleophilic attack using LDA was attempted with both 2-iodo and 
3-iodothiophene, however the yields were less than 50% in both cases (Bello, 2008).  
Thus Stille coupling was chosen as a method of choice for subsequent synthesis. 
The coupling of 4-iodopyrazole to compound 14 (Scheme 4a) presented 
challenges, and moderate yields (50-60%) were observed compared to those with 2- or 3-
iodothiophene. The first problem was seen when the 1H NMR spectrum was recorded on 
a presumed pure product isolated from the column chromatography. All desired peaks 
were present, however there was a set of three extra peaks at ~7.5 ppm (specific ppm 
values) and the peak areas were in the ratio 2:1:2. After purifying the compound again, 
the peaks were still present in the same ratio to each other, but in a different ratio to 
known product peaks, leading to the conclusion that they were an impurity rather than 
attached to the compound. Based on the location and ratio, the impurity was suspected to 
be a substituted phenyl group, which was supported by the fact that the catalyst for the 
reaction was palladium triphenylphosphine. Based on this information, purification 
solvents were changed from ethyl acetate and hexanes to methanol and chloroform, from 
0-4% MeOH:CHCl3. After these efforts, the product was obtained in its pure form. The 
attempts to purify the nucleotide of this compound are ongoing. 
Stille coupling did not yield products when performed with 4-iodoimidazole and 
2-bromofuran. When 2-bromofuran was reacted with the fully protected 6-tributyltin 
uridine, the tributyltin group was lost, yielding fully protected uridine. This led to the 
conclusion that it was the bromide as the halogen that was impeding the success of this 
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reaction, and as iodated furans were not available, this method was not useful to prepare 
the target compounds in this project. 
A mechanism involving direct nucleophilic attack (Scheme 7) was also attempted 
with the 2-bromofuran using LDA, and the TLC indicated that the reaction may be 
successful. However, as soon as the reaction was quenched or exposed to moisture, the 
presumed product was spontaneously converted to fully protected uridine (5). Several 
work up procedures were attempted, to reduce the amount of water in the reaction 
mixture, including a 1:1 mixture of ethyl acetate and saturated NH4Cl, but all resulted in 
the same reversion to fully protected uridine.  
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Scheme 7. Mechanism involving direct nucleophilic attack of C-6 lithiated uridine onto 
2-bromouridine. 
 
When Stille coupling was attempted with 4-iodoimidazole, the TLCs used to 
monitor the reaction were extremely messy, containing 4-6 separate spots. This reaction 
was tried multiple times with similar results. Purification was attempted, and fractions 
tested using 1H and 13C NMR and UV, but all gave inconclusive results. As two other 
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derivatives with nitrogen heterocycles had been successfully prepared, this compound 
was abandoned at this point. 
 
III.b. Click Chemistry 
 Click chemistry is a term used to describe a set of reliable, quick and 
selective reactions by joining small reactive units, usually through hetero-atom link, to 
generate specific substances (Leuven, 2007). The term was first used by H.C. Kolb, M.G. 
Finn and K.B. Sharpless in 2001 and has three main classes, including nucleophilic 
opening of spring-loaded electrophiles, condensation reactions of carbonyl compounds 
and cycloaddition reactions (Kolb, 2001; Leuven, 2007). The mechanism used for the 
synthesis of 6-tetrazole UMP (Schemes 8-10) falls into the third category. In this 
mechanism, 5-bromo fully protected uridine (18) was prepared, then converted to 6-
cyano fully protected uridine (19) (Kumar, 1994; Ueda, 1975; Poduch, 2006). This was 
then cyclized using the Click Chemistry methodology with NaN3 to form 6-tetrazole fully 
protected uridine (20) (Kumar, 1996; Poduch, 2006). This synthesis can be seen in the 
following scheme, Scheme 11, and was based on previous synthesis of C6-derivatives by 
Poduch et al. (Poduch, 2006; and references cited there in). 
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Scheme 8. Reaction mechanism for the formation of 5-bromo from fully protected 
uridine. 
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Scheme 9. Reaction mechanism for the formation of 6-cyano from the 5-bromo fully 
protected uridine derivative. 
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Scheme 10. Reaction mechanism for the formation of 6-tetrazole from the fully protected 
6-cyano uridine derivative. 
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Scheme 11. Synthesis for the formation of 6-tetrazolyl-UMP using click chemistry 
methodology. Reaction conditions: (a) 1,2-dimethoxyethane, NaN3, H2O, N-
bromosuccinimide (b) NaCN, DMF (c) NaN3, NH4Cl, DMF, 90 °C. 
  
This method of synthesizing 6-tetrazole uridine had previously been successful, 
but after deprotection, the researchers had been unable to properly purify, and so could 
not get pure 6-tetrazole uridine or go on to make 6-tetrazole uridine-5'-monophosphate 
(Bello, 2008). Purification problems first occurred with the fully protected compound. 
The tetrazole group, which is highly polar, imposed a high polarity on compound when 
attached, making regular phase separation difficult. However, the TBDMS and 
isopropylidene protecting groups countered this increased polarity and so reverse phase 
separation was unsuccessful.  
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Purification was tried using a manual silica gel column, with solvent gradients 
from 0-10% MeOH:CHCl3, however triethylamine (up to 5%) had to be used to 
neutralize the acidic nature of the silica gel. The pure product was obtained by this 
method, however the triethylamine could not be extracted even after several attempts of 
neutralization with 1% HCl and extraction with ether.  
Compound 20 was also purified with manual column using up to 30% MeOH 
without triethylamine, but this high concentration of MeOH caused the silica gel to 
dissolve and come through the column with product. Finally, the column was tried on a 
column instrument (Biotage), which allows control of the flow rate. With the highest 
flow rate recommended for column size, the compound was able to be successfully 
separated with only 20% MeOH in CHCl3. After successful purification, it was seen that 
a partially deprotected side product was also synthesized during the reaction ( compound 
21). 
After the deprotection of the compound, it was highly polar and able to be 
separated using reverse phase C18 silica gel column on a Biotage, yielding the pure 6-
tetrazole uridine. This was unable to be accomplished with a manual reverse phase 
column, mainly because of the inability to control flow rate. Once the pure product was 
obtained successfully, monophosphorylation at the 5' position was feasible. This reaction 
proceeded smoothly, however the starting material (6-tetrazolyl uridine, 12) and product 
(6-tetrazolyl UMP, 13) could not be separated using the reverse phase C18 column on the 
Biotage™ separation unit, as both came with the solvent front in 100% water. Solvent 
gradients using 50% acetonitrile in water and water with 1% acetic acid were used, with 
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neither producing the desired results. However, separation was achieved using a C18 
reverse phase analytical column on HPLC with a gradient of 0-20% acetonitrile in 1% 
HCl:H2O solution. Attempts to use this method of separation at the preparatory level and 
obtain the pure compound are ongoing. 
 
III.c. Preparation of 6-Nitrouridine Analog 
 While adding a nitro group at the C5 position of UMP has proved to be possible, a 
method for adding a C6 nitro group is still elusive. The method tried here was done by 
converting 6-iodouridine to 6-nitrouridine using an Ullmann-type synthesis shown to 
work previously on aromatic compounds (Scheme 9) (Saito, 2005). This synthesis 
proceeds using a copper catalyst, ligand, and nitrite salt added to the halide (Scheme 12) 
(Saito, 2005). It was shown to work on aromatic rings with various substitutions, and 
since the uracil ring of UMP mimics an aromatic, this seemed a reasonable approach to 
the synthesis (Saito, 2005).  However, when this reaction was tried as shown, the TLCs 
obtained during and after the reaction were extremely messy, with more than five 
additional compounds with very poor resolution due to smearing. The starting material 
was lost during the reaction, leading to the conclusion that a stronger nitrite salt might 
lead to the desired results, such as sodium nitrite, potassium nitrite or silver nitrite. Also, 
the temperature could be increased to up to 120 °C without degradation of the starting 
material. Any of these modifications could potentially produce results, however due to 
time constraint, they were unable to be tested. 
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Scheme 12. Attempted synthesis for the formation of 6-nitro from fully protected 6-iodo 
derivative. Reactions conditions: (a) LDA, THF, iodine, -78 °C (b) DMF, copper powder, 
tetrabutylammonium nitrite, N,N’-dimethylethylenediamine, 100 °C. 
 
III.d. Stability of Compounds 
 All final compounds that were successfully isolated were stable over the course of 
up to three days at room temperature, according to 1H NMR obtained over the time 
period. However, compounds themselves were still stored in airtight containers at 0 °C. 
One intermediate, the 6-tributyltin uridine derivative, was unstable over several days if 
left at room temperature. If stored at 0 °C in an airtight container, the compound would 
last for several weeks. After this, it would slowly break down and produce low yield or 
completely unsuccessful reactions when used. 
 
III.e. Biological Testing 
 For the biological testing of the final nucleoside compounds, they were tested 
against both malaria parasites (P. falciparum) and cancer cell lines (OCI-AML1). For this 
type of testing, the compound must not have the monophosphate, or it will not be able to 
enter through the cell membrane. The nucleotide derivatives were tested against the pure 
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enzyme, ODCase, using an ITC200. For both 6-(thiophen-2-yl) uridine and 6-(thiophene-
3-yl) uridine, the IC50 value for anticancer activity was >50 µM and for antimalarial 
activity was >300 µM. For the inhibition of ODCase, IC50 value of the monophosphates 
of these two compounds was >200 µM. The biological testing for the 6-(pyrazol-4-yl) 
and 6-(tetrazol-4-yl) uridine and monophosphate compounds is currently in progress. 
 
 
 
CHAPTER IV  
CONCLUSIONS AND FUTURE DIRECTIONS 
 Over the course of the time spent working on this project as research towards a 
masters degree in chemistry, good accomplishments have been made. The formation of 
C−C bonds is known to be a stumbling block in many syntheses, although coupling 
reactions such as Negishi and Stille coupling have made it easier. While the compounds 
tested did not show the desired antimalarial or anticancer activity, eight novel compounds 
have been synthesized using old and new methods. These compounds are 6-(thiophen-3-
yl) uridine (6), 6-(thiophen-2-yl) uridine (8), 6-(pyrazol-4-yl) uridine (10) and 6-(tetrazol-
4-yl) uridine (12), along with the corresponding nucleotides, 6-(thiophen-3-yl) uridine-5’-
monophosphate (7), 6-(thiophen-2-yl) uridine-5’-monophosphate (9), 6-(pyrazol-4-yl) 
uridine-5’ monophosphate (11) (impure) and 6-(tetrazol-4-yl) uridine-5’-monophosphate 
(13) (impure). These final compounds can be seen in Figure 3. The two impure 
compounds are in the process of being purified for biological testing. 
 Some C6-UMP derivatives have already given promising results, and the 
synthesis of a variety of these derivatives will only increase the likelihood of finding a 
potent and reliable inhibitor of ODCase that can become a potential malaria drug. The 
easier it is to create novel, C6 derivative compounds of uridine, the faster this goal can be 
accomplished. The research presented here supports this in presenting a method that 
could be used to create many different compounds. 
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  If a method could be found based on the method in this research for the synthesis 
of 6-nitrouridine and its monophosphate, the potential for that compound would be huge. 
The continuation of this research, with support from computational design efforts, could 
potentially produce a new antimalarial, helping to curb this deadly disease and save the 
lives or improve the lifestyles of millions. 
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